ArticleNaunyn-Schmiedeberg's archives of pharmacology2010
Postjunctional α2C-adrenoceptors mediate vasoconstriction in rat tail artery: influence of precontraction and temperature on vasoreactivity.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 13 citations in OpenAlex.
- Higenamine exerts an antispasmodic effect on cold-induced vasoconstriction by regulating the PI3K/Akt, ROS/α2C-AR and PTK9 pathways independently of the AMPK/eNOS/NO axis.Experimental and therapeutic medicine · 2019Article
- Alpha2C-adrenoceptors play a prominent role in sympathetic constriction of porcine pulmonary arteries.Naunyn-Schmiedeberg's archives of pharmacology · 2012Article
- Intracellular α(2C)-adrenoceptors: storage depot, stunted development or signaling domain?Biochimica et biophysica acta · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The isolated rat tail artery (RTA) represents an in vitro model of the cutaneous circulation. We have characterised the postjunctional α(2)-adrenoceptor subtype mediating vasoconstriction to the α(2)-adrenoceptor (α(2)-AR) agonist UK14304 in RTA. In non-precontracted arterial rings at 32°C, a physiological temperature for the RTA, UK14304 elicited only slight contractions which were markedly enhanced after precontraction with serotonin (5-HT; 10-50 nM). Under the condition of elevated vascular tone, the contractile UK14304 response was competitively antagonised by MK912 (pA(2) = 10.05 ± 0.07), rauwolscine (pA(2) = 8.82 ± 0.06), yohimbine (pA(2) = 8.45 ± 0.04), WB4101 (pA(2) = 8.05 ± 0.05), BRL44408 (pA(2) = 7.20 ± 0.04), ARC239 (pA(2) = 6.90 ± 0.05) and prazosin (pA(2) = 6.80 ± 0.05). Schild regressions were linear and had slopes of unity. Affinities (pA(2)) for MK912, rauwolscine, yohimbine and WB41104 were in the same range as binding data (pK(D)) for these drugs at α(2C)-ARs of rat cerebral cortex. In addition, the presence of α(2C)-ARs was confirmed by Western blotting. In experiments to study the influence of temperature on vasoreactivity, UK14304-induced contractions did not differ at 37°C, 32°C or 27°C and were similarly blocked by rauwolscine (apparent pA(2) = 8.73-8.90). After rapid cooling (from 37°C to 27°C), the maximal UK14304 response was enhanced only in precontracted arteries; antagonism by rauwolscine was the same before and after cooling (apparent pA(2) = 8.80-8.90). The enhancement of the maximal UK14304 response was abolished by rewarming to 37°C. It is concluded that α(2C)-ARs predominantly mediated vasoconstriction in RTAs at any temperature tested. Since α(2C)-ARs may be involved in Raynaud's phenomenon, the isolated RTA represents a convenient in vitro bioassay to test novel compounds for the treatment of this syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.